{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-036860","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2023-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.716570+00:00","generated_at":"2026-06-17T14:56:46.718190+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Jaguar Health reports 2022 prescription revenue up 179% to $11.9M; net loss narrows to $48.4M","bullets":["Prescription product net revenue $11.9M for 2022, up 179% YoY from $4.3M in 2021.","Net loss attributable to common shareholders $47.5M ($36.18 per share) vs $52.6M in 2021.","Cash position approximately $15.3M as of March 24, 2023.","Phase 3 OnTarget trial enrollment at ~80%; completion expected in Q2 2023.","Orphan Drug Designation granted for crofelemer for MVID; IND submission planned Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-036860","json":"https://secwatch.observer/filing/0001104659-23-036860.json","markdown":"https://secwatch.observer/filing/0001104659-23-036860.md","text":"https://secwatch.observer/filing/0001104659-23-036860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923036860/0001104659-23-036860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923036860/tm2310147d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T14:56:46.718190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"420d7801ea7e93ec307b16ed397f6b6610049342","claim":"Jaguar Health, Inc. reported the year ended December 31, 2022 results: revenue approximately $11.9 million.","evidence_excerpt":"Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended December 31, 2021, an increase of 178.7%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923036860/0001104659-23-036860-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"approximately $11.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}